Protocol Ledger

NCT05600894 · Phase II · ACTIVE NOT RECRUITING

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Interventional Phase II clinical trial protocol NCT05600894 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-27 Enrollment: 132 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05600894
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)132 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05600894
Protocol FieldVerified Registry Value
NCT IdentifierNCT05600894
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment132 participants (ESTIMATED)
Registered Start Date2023-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI